Retatrutide

Retatrutide is a peptide currently in clinical trials as a next-generation obesity and metabolic treatment. It functions as a triple agonist, simultaneously targeting the GLP-1 (glucagon-like peptide-l), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors — making it one of the most advanced peptides in the field of metabolic regulation and weight management.

By activating all three pathways, Retatrutide has demonstrated unprecedented fat loss, improved glucose metabolism, and potential enhancements in energy expenditure. In early clinical trials, it has shown greater weight loss than semaglutide (Ozempic/Wegovy) or tirzepatide

(Mounjaro/Zepbound).